NCT05454241

CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

Efficacy, Safety and PK of CD7 CAR-T in Patients With Relapsed or Refractory CD7+ Hematological Malignancies

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 3 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological malignancies.

Conditions

• Hematological Malignancies

Interventions

Type	Name	Description
DRUG	Anti-CD7 CAR-T	Universal CAR-T cells targeting CD7

Timeline

• Start date: 2022-09-07
• Primary completion: 2024-08-31
• Completion: 2024-08-31
• First posted: 2022-07-12
• Last updated: 2025-03-13

Locations

1 site across 1 country: China